MAP kinase inhibition for the prevention of post-ERCP pancreatitis.
Latest Information Update: 03 Sep 2021
At a glance
- Drugs Semapimod (Primary)
- Indications Pancreatitis
- Focus Therapeutic Use
- Acronyms CNI study
- Sponsors Cytokine PharmaSciences
- 03 Sep 2021 New trial record